Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.
Laurence Greenhill, Scott Kollins, Howard Abikoff...
https://pubmed.ncbi.nlm.nih.gov/17023867/Actively Recruiting
Led by Daniel Coury · Updated on 2026-10-22
500
Participants Needed
13
Research Sites
51 weeks
Total Duration
Researchers are evaluating the effectiveness of two stimulant medications, methylphenidate and amphetamine, for treating ADHD in children and adolescents who also have autism spectrum disorder ASD. This study uses a special design called a Sequential Multiple Assignment Randomization Trial SMART to compare these medications and also assess the role of alpha-2 agonists, another class of ADHD medication. The goal is to improve how doctors choose medications and reduce the trial-and-error process that families currently face. Participants are first randomly assigned to receive either an amphetamine or methylphenidate medication, with the specific choice made through discussion between the doctor and the parent or caregiver. If the first medication is not effective or tolerable, participants may be re-randomized to either an alpha-2 agonist or the alternate stimulant. Medications are obtained through the participants pharmacy, and dosing and duration are personalized through discussions between the doctor and family. This study does not involve investigational drugs but rather evaluates commonly prescribed medications. During the study, parents will regularly provide ratings of their childs response to medication using standardized tools such as the Vanderbilt Parent Rating Scale, Clinical Global Impression, and the Aberrant Behavior Checklist. Most assessments are completed electronically to minimize hospital visits. The study aims to gather detailed information over 16 weeks to understand medication effectiveness, side effects, and impacts on behaviors. Participants are children aged 4 to 17 years, and the findings will help improve medication management for children with both ASD and ADHD.
CONDITIONS
AWARE: Management of ADHD in Autism Spectrum Disorder
A
Amanda James, BS
S
Samantha Sharpe
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Daniel Coury
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Amphetamine‑ or Methylphenidate‑class stimulant first | Alpha‑2 agonist or alternate stimulant second line | Typical stimulant first‑line in practice |
|---|---|---|---|
| What the approach is | Randomized to start treatment with either an amphetamine‑class or methylphenidate‑class stimulant as first‑line therapy | If first‑line stimulant is not effective or tolerable, randomized again to an alpha‑2 agonist or the alternate stimulant class | In typical practice, stimulants like methylphenidate or amphetamines are started as first‑line ADHD treatment, even in children with ASD |
| Primary use | Initial pharmacologic management of ADHD symptoms in children with ASD | Alternative treatment when initial stimulant is ineffective or poorly tolerated | Common first‑line ADHD pharmacotherapy as generally used in real‑world pediatric care |
| Evidence status (outside of this trial) | Stimulants have known efficacy for reducing ADHD symptoms in children with ASD but may require slower titration and careful monitoring | Alpha‑2 agonists show promising benefit for hyperactivity, impulsivity, irritability and attention deficits in ASD, though evidence is not yet definitive | Stimulants are well‑established first‑line treatment in guidelines for ADHD with or without ASD |
| Important risks | Stimulants may cause higher rates of side effects and behavioral activation in children with ASD, requiring cautious dosing | Alpha‑2 agonists may be associated with sedation and delayed therapeutic onset | Stimulant side‑effect profiles are well‑documented but may vary when ASD is present |
| Important limitations | The trial does not yet report comparative effectiveness or tolerability data between stimulant classes in ASD | Evidence for alpha‑2 agonist use in ASD‑ADHD is promising but based on small studies and short‑term outcomes | Standard stimulant use may be less tolerable or effective in ASD, prompting need for alternative strategies |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - Up to 16 weeks
Participants are randomly assigned to receive either an amphetamine or methylphenidate medication. The specific medication is chosen through discussion between the doctor and parent or caregiver, considering insurance coverage. Participants obtain medications from their pharmacy.
Regular assessments every 2 weeks and monthly parent questionnaires
Duration - Up to 16 weeks
If the first medication is not effective or tolerable, participants are re-randomized to receive either an alpha-2 agonist or the alternate stimulant medication. Dosage and duration are discussed between the study doctor and family.
Ongoing assessments similar to Stage 1
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Laurence Greenhill, Scott Kollins, Howard Abikoff...
https://pubmed.ncbi.nlm.nih.gov/17023867/Thomas J Spencer, Timothy E Wilens, Joseph Biederman...
https://pubmed.ncbi.nlm.nih.gov/16678648/Paul S Carbone, Diane D Behl, Virgina Azor...
https://pubmed.ncbi.nlm.nih.gov/19768528/Daniel L Coury, Donna S Murray, Angie Fedele...
https://pubmed.ncbi.nlm.nih.gov/32238527/Patricia Pastor, Cynthia Reuben, Catherine Duran...
https://pubmed.ncbi.nlm.nih.gov/25974000/Elizabeth Harstad, Justine Shults, William Barbaresi...
https://pubmed.ncbi.nlm.nih.gov/33946100/C Lord, M Rutter, A Le Couteur
https://pubmed.ncbi.nlm.nih.gov/7814313/Floyd R Sallee, James McGough, Tim Wigal...
https://pubmed.ncbi.nlm.nih.gov/19106767/Jeffrey H Newcorn, Christopher J Kratochvil, Albert J Allen...
https://pubmed.ncbi.nlm.nih.gov/18281409/Rakesh Jain, Scott Segal, Scott H Kollins...
https://pubmed.ncbi.nlm.nih.gov/21241954/Daniel Coury
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborating Sponsor